Corticotropin releasing factor receptor antagonists
US11351177B2 · kind B2 · utility
5Cited by
3References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 25, 2021 |
| Grant date | Jun 7, 2022 |
| Priority date | — |
| Expiry date | Jun 25, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides novel pharmaceutical compositions comprising-(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.